Recurrent, metastatic disease represents the most frequent cause of death for patients with
thyroid cancer, and radioactive iodine (RAI) remains a mainstay of therapy for these patients …

Understanding the molecular landscape of cancer has facilitated the development of
diagnostic, prognostic, and predictive biomarkers for clinical oncology. Developments in …

Mutational signature analysis is commonly performed in cancer genomic studies. Here, we
present SigProfilerExtractor, an automated tool for de novo extraction of mutational …

As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase
(ALK) has been validated to play important roles in various cancers, especially anaplastic …

Thyroid cancer comprises different clinical and histological entities. Whereas differentiated
(DTCs) malignancies are sensitive to radioiodine therapy, anaplastic (ATCs) and medullary …

Thyroid cancer is the most common endocrine malignancy. Knowledge of the molecular
pathology of thyroid tumours originating from follicular cells has greatly advanced in the past …

Improvement in the clinical outcome of human cancers requires characterization of the
genetic alterations underlying their pathogenesis. Large‐scale genomic and transcriptomic …

The use of external‐beam radiotherapy (EBRT) in differentiated thyroid cancer (DTC) is
debated because of a lack of prospective clinical data, but recent retrospective studies have …

Background: The BRAFV600E mutation in papillary thyroid carcinoma (PTC) is particularly
prevalent in Korea, and a considerable number of wild-type BRAF PTCs harbor RAS …

Background: BRAFV600E and N/H/K RAS mutations and oncogenic kinase fusions
involving neurotrophin tyrosine receptor kinase (NTRK), RET, anaplastic lymphoma kinase …